Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 391-400 of 639 results
PLoS ONE, 2018 • March 26, 2018
This study investigated the effects of pharmacologic sclerostin inhibition and testosterone administration on muscle atrophy in rats after spinal cord injury (SCI). Sclerostin inhibition did not preve...
KEY FINDING: Sclerostin antibody (Scl-Ab) did not prevent soleus muscle atrophy after spinal cord injury (SCI) in rats.
Toxins, 2018 • March 28, 2018
This retrospective observational study evaluated the efficacy and safety of IncobotulinumtoxinA in managing muscle spasticity, using doses from 100 to 1000 units, tailored to individual patient needs....
KEY FINDING: IncobotulinumtoxinA demonstrates a wide therapeutic window, allowing for safe and effective spasticity management with doses ranging from 100 to 1000 units, tailored to individual patient needs.
Toxins, 2018 • June 1, 2018
This review examines the mechanism of central neuropathic pain and assesses the effect of BTX on central neuropathic pain. The review summarizes the mechanism of central neuropathic pain and botulinum...
KEY FINDING: BTX inhibits the secretion of substance P and CGRP from dorsal root ganglion (DRG) neurons, reduces the expression of TRPV1 and P2X3 receptors, and induces a central effect through retrograde axonal transport, all of which contribute to its potential analgesic effects.
The Journal of Spinal Cord Medicine, 2019 • May 1, 2019
This retrospective study evaluated the effectiveness of botulinum toxin (BT) injections in treating spasticity in 90 patients with spinal cord injury (SCI). The results indicated that BT injections im...
KEY FINDING: Patients with focal spasticity experienced a significantly greater improvement in muscle tone compared to those with generalized spasticity.
Molecular Pain, 2018 • June 8, 2018
This study investigates the therapeutic potential of Pak1 inhibition for pain associated with cutaneous burn injury using romidepsin, an FDA-approved inhibitor. The findings demonstrate that Pak1 inhi...
KEY FINDING: Inhibition of Pak1 by romidepsin decreased dendritic spine dysgenesis in the dorsal horn of mice with burn injury.
The Journal of Spinal Cord Medicine, 2019 • January 1, 2019
This study evaluated the impact of long-term nitrofurantoin for UTI prophylaxis in veterans with SCI. Long-term prescription of nitrofurantoin may reduce UTIs in veterans with SCI and there is no evid...
KEY FINDING: UTIs were less frequent in cases receiving long-term nitrofurantoin compared to controls.
Neurotherapeutics, 2018 • August 6, 2018
This editorial provides an overview of current research in spinal cord injury (SCI) therapeutics, highlighting the challenges in developing effective treatments for SCI. It presents a collection of pa...
KEY FINDING: The review papers assembled match the temporo-spatial progression of SCI, from acute considerations at the site of injury, to subacute processes at and beyond the injury, to chronic changes away from the site of injury.
Spinal Cord Series and Cases, 2018 • June 7, 2018
The author argues that cannabis is an effective pain reliever for individuals with spinal cord injuries and should be more accessible for both patients and researchers. The paper highlights the histor...
KEY FINDING: Patients with SCI and chronic pain report cannabis as the single most effective medication out of 26 pain treatments.
Spinal Cord Series and Cases, 2018 • May 26, 2018
Cannabis presents a complex challenge due to its intricate effects on the central nervous system. Practitioners hold differing opinions on cannabis, awaiting more definitive evidence regarding its the...
KEY FINDING: The composition of cannabis sativa is complex, consisting of hundreds of cannabinoids as well as terpenes, flavinoids, and phenoids.
Neural Regen Res, 2018 • September 1, 2018
This study investigates the effect of Saikosaponin a (SSa) on nerve regeneration and scar formation following sciatic nerve injury (SNI) in rats. SSa is a molecule with known anti-inflammatory propert...
KEY FINDING: Saikosaponin a (SSa) treatment significantly increased interleukin-10 (IL-10) levels in rats with sciatic nerve injury (SNI) 7 days after injury, indicating an enhanced anti-inflammatory response.